Business Wire

Strong Customer Gains and Standout US Growth Helps Entersekt Solidify Market Position

16.8.2023 12:00:00 EEST | Business Wire | Press release

Share

Entersekt, a global leader in transaction authentication solutions for financial fraud prevention, today announced strong growth in both revenue and number of customers, fueled by continued US expansion and strategic partnerships. Since the investment by Accel-KKR in fiscal 2022, Entersekt has seen its business outside of South Africa accelerate rapidly with contracted annual recurring revenue increase by 191%, and nearly 220% growth in US-based customers in fiscal 2023 alone.

“Our solid growth in a difficult global business climate is testament to Entersekt’s innovation and expertise addressing emerging fraud threats,” said Schalk Nolte, Entersekt CEO. “Our reputation of delivering the highest level of security to financial institutions across all digital channels without compromising user experience is capturing the attention of decision makers – many of whom now recognize the urgent need to adopt more robust authentication methods to replace the traditional approaches that are proving to be vulnerable to increasingly sophisticated fraud attempts.”

“We are particularly pleased with our performance in the US which is nearing hypergrowth. The region remains a key focus for the year ahead and we have identified key partners and talent who are well known in the industry to help us to accelerate the current trajectory. The market has shown itself eager to adopt our technology which has a proven track record with financial institutions around the world,” Nolte explained.

“As fraud and financial crime continues to threaten financial institutions around the world, the opportunity for innovative technology firms to help mitigate these risks is greater than ever,” said Julie Conroy, Head of Risk Insights at Datos Insights. “Entersekt’s steady growth and expansion is a key indicator of the appetite for FIs of all sizes to seek solutions that can reduce fraud while ensuring an optimal user experience.”

Fiscal 2023 Performance Highlights

Market-leading fraud prevention Innovations
The Entersekt team continued to innovate well ahead of the industry curve, with three new patents granted in FY2023, adding to the more than 60 existing technology patents. These include Context Aware™ Authentication which is the first cross-channel fraud prevention to consider the originating channel, the transaction context, the analysis and orchestration of both active and silent risk signals, the available authentication mechanisms, as well as the customer’s choice to determine the most appropriate authentication journey - all in real-time.

“Many banks continue to struggle with siloed authentication mechanisms, with different solutions for online banking, in-branch offerings, call centers, digital payments and open banking, with each using its own authentication technology. We're providing the ability to break down all those silos and have one common authentication platform across all the various channels. Not only does this provide a much better user and customer experience, but also helps orchestrate all that data to help banks make better decisions,” Nolte said.

New strategic channel and technology partnerships
The Entersekt team continued to solidify new partnerships in all regions, improving it’s go-to-market scale and creating new market opportunities. By supporting pre-integration, these partnerships enabled banks to quickly and easily deploy Entersekt’s state-of-the-art authentication technology. Most recently, Entersekt’s biometric authentication technology was integrated into Q2’s Digital Banking Platform, adding biometric authentication capabilities to the Q2 online and mobile banking applications.

Expanded senior management
To support the significant growth and opportunity in the US market, Entersekt made ten new director, VP or C-level hires in the US in FY23. Its executive team and company headquarters is now based both in the US and South Africa, showcasing the importance of and commitment to regional representation.

Three new C-level appointments, all with decades of leadership experience, include Matt Loos as Chief Revenue Officer, Pradheep Sampath as Chief Product Officer and Frank Moreno as Chief Marketing Officer.

  • Loos joins Entersekt with over 20 years of leadership experience at companies like Fifth Third Bank, Cardinal Commerce and Mastercard.
  • Sampath has led new product initiatives for over 20 years, scaling SaaS, mobile and API-based products for companies like ID.me and GXS.
  • Moreno’s experience includes senior marketing leadership roles spanning over 20 years with tech companies such as Bottomline and Datawatch.

More growth on the horizon
Looking ahead, Nolte said the industry must prepare for the continued challenges of account takeover fraud schemes and authorized push payment fraud, saying the rise of real-time payments, particularly through mobile apps, has introduced a need for faster and more effective fraud detection mechanisms.

“Our vision for the future is centered around becoming a leading force in the digital landscape, revolutionizing the way people conduct secure transactions on digital platforms. With the backing of our US-based investors, key partners and a customer-centric approach, we are poised for exceptional success in the year ahead and beyond,” Nolte said.

About Entersekt
Entersekt ensures that digital financial transactions are secure and free from unnecessary friction. The company provides a single cross-channel platform for financial services institutions to meet authentication requirements and optimize user experiences. With a range of options available for deployment and configuration, Entersekt’s solutions are fully customizable across all channels and devices. A strong track record of over ten years’ working with leading financial services institutions across the United States, Europe, and Africa, combined with multiple patented security innovations, has established Entersekt as a global industry leader in authentication. Backed by companies like Silicon Valley-based Accel-KKR, one of the world’s top private equity firms, Entersekt continues to expand its footprint across key regions. For more information, visit entersekt.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Frank Moreno
Chief Marketing Officer
frank@entersekt.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release

Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye